These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Unilateral gynecomastia and impotence during low-dose spironolactone administration in men. Zarren HS; Black PM Mil Med; 1975 Jun; 140(6):417-9. PubMed ID: 807887 [No Abstract] [Full Text] [Related]
5. Antialdosterones: incidence and prevention of sexual side effects. de Gasparo M; Whitebread SE; Preiswerk G; Jeunemaître X; Corvol P; Ménard J J Steroid Biochem; 1989 Jan; 32(1B):223-7. PubMed ID: 2913412 [TBL] [Abstract][Full Text] [Related]
6. Antiandrogenic effects of spironolactone: hormonal and ultrastructural studies in dogs and men. Baba S; Murai M; Jitsukawa S; Hata M; Tazaki H J Urol; 1978 Mar; 119(3):375-80. PubMed ID: 642094 [TBL] [Abstract][Full Text] [Related]
8. Absence of progestational activity of oral spironolactone. Nakajima ST; Brumsted JR; Riddick DH; Gibson M Fertil Steril; 1989 Jul; 52(1):155-8. PubMed ID: 2744183 [TBL] [Abstract][Full Text] [Related]
9. Effect of spironolactone on sex hormones in man. Stripp B; Taylor AA; Bartter FC; Gillette JR; Loriaux DL; Easley R; Menard RH J Clin Endocrinol Metab; 1975 Oct; 41(4):777-81. PubMed ID: 1176584 [TBL] [Abstract][Full Text] [Related]
10. Effects and side-effects of spironolactone therapy in women with acne. Yemisci A; Gorgulu A; Piskin S J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):163-6. PubMed ID: 15752283 [TBL] [Abstract][Full Text] [Related]
11. Gynecomastia induced in normal males by spironolactone. Huffman DH; Kampmann JP; Hignite CE; Azarnoff DL Clin Pharmacol Ther; 1978 Oct; 24(4):465-73. PubMed ID: 688736 [No Abstract] [Full Text] [Related]
12. Cimetidine is an antiandrogen in the rat. Winters SJ; Banks JL; Loriaux DL Gastroenterology; 1979 Mar; 76(3):504-8. PubMed ID: 428705 [TBL] [Abstract][Full Text] [Related]
13. Pathophysiology of spironolactone-induced gynecomastia. Rose LI; Underwood RH; Newmark SR; Kisch ES; Williams GH Ann Intern Med; 1977 Oct; 87(4):398-403. PubMed ID: 907238 [TBL] [Abstract][Full Text] [Related]
14. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy. Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D Digestion; 1989; 44(3):155-62. PubMed ID: 2697627 [TBL] [Abstract][Full Text] [Related]
15. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. Leschek EW; Jones J; Barnes KM; Hill SC; Cutler GB J Clin Endocrinol Metab; 1999 Jan; 84(1):175-8. PubMed ID: 9920079 [TBL] [Abstract][Full Text] [Related]
16. Experimental studies on the endocrine side effects of new aldosterone antagonists. Nishino Y; Schröder H; el Etreby MF Arzneimittelforschung; 1988 Dec; 38(12):1800-5. PubMed ID: 3245852 [TBL] [Abstract][Full Text] [Related]
17. [Dysfunction of the hypothalamo-hypophyseal-gonadal axis induced by histamine H2 antagonists. Review of the literature and personal observations]. Biagi P; Milani G Minerva Med; 1985 Mar; 76(12):579-86. PubMed ID: 3921876 [TBL] [Abstract][Full Text] [Related]
18. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. Laue L; Jones J; Barnes KM; Cutler GB J Clin Endocrinol Metab; 1993 Jan; 76(1):151-5. PubMed ID: 8421081 [TBL] [Abstract][Full Text] [Related]
19. Eplerenone reduces morbidity and mortality after acute MI. Cardiovasc J S Afr; 2006; 17(5):280. PubMed ID: 17117244 [No Abstract] [Full Text] [Related]
20. A novel use of spironolactone: treatment of hirsutism. Shapiro G; Evron S J Clin Endocrinol Metab; 1980 Sep; 51(3):429-32. PubMed ID: 7410528 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]